Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Transcriptomic meta-analysis of multiple sclerosis and its experimental models.
Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation.
Therapy optimization in multiple sclerosis: a prospective observational study of therapy compliance and outcomes.
Fingolimod (Gilenya) licence extended
SymptoMScreen: A Tool for Rapid Assessment of Symptom Severity in MS Across Multiple Domains.
Anti-inflammatory effects of levetiracetam in experimental autoimmune encephalomyelitis.
Ginseng in the Treatment of Fatigue in Multiple Sclerosis: A Randomized Placebo-Controlled Double-Blind Pilot Study.
Does a waist-worn ActiGraph accelerometer quantify community ambulation in persons with multiple sclerosis?
Immune reconstitution inflammatory syndrome in a patient treated with natalizumab presenting progressive multifocal leukoencephalopathy.
Sustained-Release Fampridine (4-Aminopyridine) in Multiple Sclerosis: Efficacy and Impact on Motor Function.
[Oral disease modifying therapy of multiple sclerosis: the current view.]
Interventions to evaluate fitness to drive among people with chronic conditions: Systematic review of literature.
The effect of vitamin A supplementation on stimulated T-cell proliferation with myelin oligodendrocyte glycoprotein in patients with multiple sclerosis.
Relapsing-remitting multiple sclerosis and chronic idiopathic neutropenia: a challenging combination.
In vivo identification of morphologic retinal abnormalities in neuromyelitis optica.
Progressive multiple sclerosis and mood disorders.
Integrin/Chemokine Receptor Interactions in the Pathogenesis of Experimental Autoimmune Encephalomyelitis.
Merck KGaA Reaches Mutual Agreement with Ono Pharmaceutical to Terminate the License Agreement on Ceralifimod (ONO-4641)
Deafness in Patients with Multiple Sclerosis.
Microparticle Platform
Cerebrospinal fluid α-synuclein levels are elevated in multiple sclerosis and neuromyelitis optica patients during replase.
Accidental natalizumab administration in pregnancy in multiple sclerosis.
Complement receptor-3 negatively regulates the phagocytosis of degenerated myelin through tyrosine kinase Syk and cofilin.
Do cortical lesions help us to distinguish MS from NMO?
Multiple sclerosis and pregnancy: maternal considerations.

Pages